2639 Results

People

  1. Zelenetz
    Zelenetz
  2. Horwitz
    Horwitz
  3. Palomba
    Palomba
  4. Noy
    Noy
  5. Moskowitz
    Moskowitz
  6. Younes
    Younes
  7. Matasar
    Matasar
  8. Moskowitz
    Moskowitz
  9. Yahalom
    Yahalom
  10. Portlock
    Portlock

Groups

  1. Center for Hematologic Malignancies (2639)
  2. Department of Medicine (2639)
  3. Hematologic Malignancies, Division of (2639)
  4. Lymphoma (2639)
  5. Population Sciences Research Program (720)
  6. Survivorship Research (633)
  7. Executive Committee, Center for Hematologic Malignancies (389)
  8. Epidemiology and Biostatistics (363)
  9. GSK Faculty (356)
  10. Department of Pathology and Laboratory Medicine (300)
  1. "Lymphoma"
Formats
  1. Meeting Abstract (1340)
  2. Journal Article (1048)
  3. Book Section (63)
  4. Review (63)
  5. Editorial (37)
  6. Research Letter (35)
  7. Guidelines (18)
  8. Conference Paper (15)
  9. Correspondence (11)
  10. Miscellaneous (5)
  11. Book Whole (4)
Groups
  1. Center for Hematologic Malignancies (2639)
  2. Department of Medicine (2639)
  3. Hematologic Malignancies, Division of (2639)
  4. Lymphoma (2639)
  5. Population Sciences Research Program (720)
  6. Survivorship Research (633)

More Groups

People
  1. Andrew Zelenetz (767)
  2. Steven Horwitz (645)
  3. Maria Palomba (415)
  4. David Straus (356)
  5. Ariela Noy (351)
  6. Alison Moskowitz (339)

More People

Years
  1. 2025 (28)
  2. 2024 (100)
  3. 2023 (180)
  4. 2022 (170)
  5. 2021 (171)
  6. 2020 (170)

More Years

Publications
  1. Blood (833)
  2. Journal of Clinical Oncology (274)
  3. Hematological Oncology (110)
  4. Leukemia and Lymphoma (81)
  5. British Journal of Haematology (79)
  6. Haematologica (71)

More Publications

Publishers
  1. American Society of Hematology (898)
  2. American Society of Clinical Oncology (290)
  3. Elsevier Inc. (187)
  4. Wiley Blackwell (173)
  5. John Wiley & Sons (95)
  6. Nature Publishing Group (92)

More Publishers

Results (2639)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Subcutaneous mosunetuzumab is active with a manageable safety profile in patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHL): Updated results from a phase I/II study
    Meeting Abstract

    von Tresckow, B.; Budde, L. E.; Bartlett, N. L.; Giri, P.; Schuster, S. J.; Assouline, S.; Yoon, S. S.; Fay, K.; Matasar, M.; Gutierrez, N. C.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • A reproducible inflammatory biomarker signature identifies non-Hodgkin lymphoma patients at high risk of CAR-T treatment failure across different cohorts
    Meeting Abstract

    Raj, S.; Perales, M. A.; Fei, T.; Fein, J.; Tomas, A. A.; De LaPuerta, M. C.; Dahi, P.; Danylesko, I.; Epstein-Peterson, Z.; Fried, S.; more...
    Bone Marrow Transplantation (2023)

    Fulltext@MSK | Save
  • Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who received ≥2 prior therapies: Updated results from a pivotal phase II study
    Meeting Abstract

    Bartlett, N. L.; Sehn, L. H.; Matasar, M. J.; Schuster, S. J.; Assouline, S. E.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; more...
    American Journal of Hematology (2023)

    Fulltext@MSK | Save
  • Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients
    Journal Article

    Laracy, J. C.; Yan, J.; Steiger, S. N.; Tan, C. A.; Cohen, N.; Robilotti, E. V.; Fender, J.; Cohen, S.; Korde, N.; Lee-Teh, M.; more...
    Haematologica (2023)

    Fulltext@MSK | Save
  • Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement
    Journal Article

    Ryan, C. E.; Zon, R. L.; Redd, R.; Fisher, D. C.; Shouval, R.; Kumar, A.; Crombie, J. L.; Sadrzadeh, H.; Kim, A. I.; Nayak, L.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • Few and far between: Clinical management of rare extranodal subtypes of mature T-cell and NK-cell lymphomas
    Review

    Stuver, R.; Epstein-Peterson, Z. D.; Horwitz, S. M.
    Haematologica (2023)

    Fulltext@MSK | Save
  • Mosunetuzumab monotherapy demonstrates durable efficacy and manageable safety in patients with relapsed/refractory follicular lymphoma and ≥2 prior therapies: Updated results from a pivotal phase 2 study
    Meeting Abstract

    Bartlett, N. L.; Sehn, L. H.; Matasar, M.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; more...
    Journal of Oncology Navigation & Survivorship (2023)

    Fulltext@MSK | Save
  • Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing
    Journal Article

    Ptashkin, R. N.; Ewalt, M. D.; Jayakumaran, G.; Kiecka, I.; Bowman, A. S.; Yao, J. J.; Casanova, J.; Lin, Y. T. D.; Petrova-Drus, K.; Mohanty, A. S.; more...
    Nature Communications (2023)

    Fulltext@MSK | Save
  • NCCN Guidelines® Insights: B-cell lymphomas, version 6.2023
    Guidelines

    Zelenetz, A. D.; Gordon, L. I.; Abramson, J. S.; Advani, R. H.; Andreadis, B.; Bartlett, N. L.; Budde, L. E.; Caimi, P. F.; Chang, J. E.; Christian, B.; more...
    Journal of the National Comprehensive Cancer Network (2023)

    Fulltext@MSK | Save
  • Prognostic model using (18)F-FDG PET radiomics predicts progression-free survival in relapsed/refractory Hodgkin lymphoma
    Journal Article

    Driessen, J.; Zwezerijnen, G. J. C.; Schöder, H.; Kersten, M. J.; Moskowitz, A. J.; Moskowitz, C. H.; Eertink, J. J.; Heymans, M. W.; Boellaard, R.; Zijlstra, J. M.
    Blood Advances (2023)

    Fulltext@MSK | Save